Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry
Brief Summary: This study will compare the incidence of residual neuromuscular blockade in participants who undergo reversal of neuromuscular blockade with sugammadex compared to those who undergo reversal of neuromuscular blockade with usual care (neostigmine/glycopyrrolate).


Options:
A: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) Class 1 or 2 or 3
* Scheduled to undergo an elective abdominal surgical procedure under general anesthesia; and:

  * expected to undergo neuromuscular relaxation with rocuronium for

endotracheal intubation; and

* expected to require at least one maintenance dose of rocuronium; and
* expected to require active reversal of neuromuscular blockade; and
* expected to require clinical or subjective neuromuscular monitoring only; and
* expected to recover in the PACU

  * Arm that is accessible for measuring the TOF ratio in the PACU
  * Sexually active female patient of child-bearing potential must agree to use a

medically accepted method of contraception through seven days after receiving

protocol-specified medication.

Exclusion Criteria:

* Anatomical malformations that may lead to difficult intubation
* Neuromuscular disorder(s) that may affect neuromuscular blockade and/or trial assessments
* Dialysis-dependent or has or is suspected of having severe renal insufficiency
* Significant hepatic dysfunction
* Family history of malignant hyperthermia
* Cardiac pacemaker
* Allergy to study treatments or its/their excipients, to opioids / opiates, sugammadex, muscle relaxants or their excipients, or other medication(s) used during general anesthesia
* Toremifene before or within 24 hours of study drug administration
* Scheduled for an overnight stay (or \>12 hours) in PACU
* Expected transfer to an Intensive Care Unit after surgery
* Pregnant, intention to become pregnant between randomization and the Day 30 pregnancy follow-up visit
* Breast-feeding.
* Investigational drug(s) within 30 days of randomization on this study
* Participation in any other clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial
* Participant or family member is among the personnel of the investigational or Sponsor staff directly involved with this trial
B: Inclusion Criteria:

* hip or other long bone fracture undergoing operative repair
* age of 70 years or older
* the ability to communicate effectively in English (including adequate hearing)
* residence within a 50 mile radius of the BIDMC
* life expectancy 6 months or greater
* not currently on cholinesterase inhibitor therapy
* not with known hypersensitivity to cholinesterase inhibitors
* not a previous study participant or refusal

Exclusion Criteria:

* patients with sick sinus syndrome or greater than 1st degree AV block without a pacemaker
* patients with a pathologic fracture due to metastatic cancer
* patients with advanced dementia or total functional dependence.
C: Inclusion Criteria:

MUST HAVE:

General Anesthesia with volatile anesthetic

PATIENT CHARACTERISTICS

Major Criteria (Must have any 1 of the following:)

1. Planned open heart surgery
2. Medications - anticonvulsants, abuse of opiates, benzodiazepines, cocaine
3. EF\<40%
4. Prior history of awareness (recall)
5. History of difficult intubation or anticipated difficult intubation
6. ASA IV or V status
7. Aortic stenosis
8. End stage lung disease
9. Marginal exercise tolerance not secondary to musculoskeletal dysfunction
10. Pulmonary hypertension
11. Daily alcohol consumption

Exclusion Criteria:

1. Surgical procedure that prevents the use of the BIS (e.g. surgery of forehead)
2. Patient positioning prevents use of the BIS
3. Surgery with wake-up test.
4. Less than 18 years of age
5. Vulnerable populations, such as those with dementia and those unable to provide informed consent.
6. Stroke with residual neurological deficits

   -
D: Inclusion Criteria:

* Patients aged 70 years or over;
* The patient is at increased risk for developing in-hospital delirium on admission according to one or more positive answers on the VMS delirium-risk questions;
* The patient and/or proxy is able to provide written informed consent;
* The patient and/or proxy speaks either Dutch or English;
* The patient is admitted to the hospital for a general medicine or surgical specialty.

Exclusion Criteria:

* Patients presenting in the ED with delirium according to the DSM-IV criteria;
* Patients with clinically significant (cardiac) disorders: QTc interval prolongation (QTc ≥500ms), recent acute myocardial infarction, uncompensated heart failure (working diagnosis), acute coronary syndrome (ACS), arrhythmias treated with class IA and III antiarrhythmic medicinal products, history of ventricular arrhythmia, history of torsades, clinically significant bradycardia, second or third degree heart block, uncorrected hypokalaemia (potassium level 3.0 or lower);
* Patients with vascular dementia;
* Patients with Lewy Body dementia;
* Patients with Parkinson dementia;
* Patients with (a history of) hypokinetic movement disorders;
* Patients with (a history of) malignant neuroleptic syndrome;
* Patients with (a history of) serotonergic syndrome;
* Patients with (a history of) central anticholinergic syndrome;
* Patients who will be admitted to the oncology ward;
* Patients previously enrolled in the HARPOON study, or in other medical- or drug studies;
* Patients using QT prolonging drugs and/or medications of which concomitant use with haloperidol is contraindicated (clinically relevant drug interactions, 1st degree, listed in the appendix of the study protocol);
* Epilepsy;
* Substance abuse and dependence (DSM-IV criteria)
* Patients who are not able to take the study medication according to protocol (amendment)

Answer: A